Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

NCT07526961 · clinicaltrials.gov ↗

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT: Nivolumab + Ipilimumab + Chemotherapy

Sponsor

Bristol-Myers Squibb